ANNA WIYGUL: Open Payments
NPI 1619496403 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,177 in 158 payments from 40 companies in 2025. Trend: 2023 $3,145 · 2024 $3,467 · 2025 $3,177
Food & beverage: $3,177
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 19 | $326 |
| Novartis Pharmaceuticals Corporation | 16 | $309 |
| Merck Sharp & Dohme LLC | 12 | $271 |
| Gilead Sciences, Inc. | 10 | $194 |
| Janssen Biotech, Inc. | 10 | $183 |
| PFIZER INC. | 9 | $118 |
| Celgene Corporation | 5 | $112 |
| Daiichi Sankyo Inc. | 4 | $103 |
| INTUITIVE SURGICAL, INC. | 1 | $103 |
| GlaxoSmithKline, LLC. | 6 | $103 |
Products named: KEYTRUDA, Trodelvy, OPDIVO, Da Vinci Surgical System, KISQALI, REBLOZYL, VERZENIO, CABOMETYX.
Industry payments across MS — which companies pay providers there.
